Karessa changes its development strategy to facilitate the commercialization of new pharmaceuticals for impotence

Karessa Pharma AB announces today that the company has decided that the next step for the drug candidates K-01 and K-03 is to perform Proof of Concept clinical studies before pivotal studies for the projects. This is considered to facilitate the process of finding suitable commercial partners for future market launches. Because of the changed strategy, the company will present a revised overall development and registration plan for the projects concerned in the first quarter of 2017.Karessa develops new pharmaceuticals based on proven pharmaceutical substances in order to offer men with